"(13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate"@en . . . "Alprostadilum"@en . . . . . . . . . . . . . . . . . . . . . . . "approved"@en . . . . . . . "5 to 10 minutes (after a single dose), in healthy adults and neonates."@en . . . . . . . . . . . . "745-65-3"@en . "Oral, mouse: LD₅₀ = 186 mg/kg; Oral, rat: LD₅₀ = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage."@en . . . . . . "11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid"@en . "investigational"@en . . . . . . . . . "Edex"@en . . . . . . . . . . . . . . . "Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology."@en . . . . . . . "Alprostadil"@en . . "Alprostadil"@en . "Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by \u03B2- and \u03C9-oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration."@en . . . . . . . . . . . . . . "Muse"@en . . . . . . . "PGE1 \u03B1-CD"@en . . . . . . . . "Prostin vr"@en . . "PGE-1"@en . "Alprostadil Alfadex"@en . "For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology."@en . "Caverject"@en . "Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This is because, as a form of prostaglandinE1 (PGE1) it has multiple effects on blood flow. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea."@en . . "Humans and other mammals"@en . . . . "The absolute bioavailability of alprostadil has not been determined."@en . . . "Bound in plasma primarily to albumin (81% bound) and to a lesser extent alpha-globulin IV-4 fraction (55% bound)."@en . . . . . . "PGE\u2081 "@en . . "Befar"@en . . . "(11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid"@en . . "Prostaglandin e1"@en . . . .